BPMC's VOYAGER Fails, CLSD's NDA Resubmission Faces Delay, SNDX Hits New High

Today's Daily Dose brings you news about Blueprint Medicines' disappointing results from gastrointestinal stromal tumor trial; revised timeline of Clearside Biomedical's resubmission of XIPERE NDA; encouraging trial results of INOVIO's MERS coronavirus vaccine and initial data from Syndax Pharma's acute leukemia trial.

from RTT - Biotech https://ift.tt/2VNKTxP
via IFTTT